Waldsassen – The statistics portal “Statista” and the business magazine “brand eins Wissen” have selected Germany’s most innovative companies for the third time. For the second year in a row, BioVariance GmbH ranks among the

BioVariace has received a financial grant for a pioneering research project to calculate personalized dosages for psychotherapeutic drugs based on patient´s unique individual genetic biomarkers. The project “Knowledge for personalized medicine in psychiatric application” will

Waldsassen. BioVariance has developed a new technology that enables a significant improvement of medication dosing for children and thereby addresses a widespread but often overlooked issue faced by pediatricians today. “According to the WHO, 40%